| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
a Department of
Thoracic Medicine, National Heart and Lung Institute, Imperial College
School of Medicine, London SW3 6LY, UK, b Department of
Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
Correspondence to: Professor K F Chung f.chung{at}ic.ac.uk
Received 14 September 2000; Returned to authors 19 December 2000; Revised version received 30 July 2001; Accepted for publication 14 August 2001
BACKGROUND
Interleukin
5 (IL-5) has an important role in mobilisation of eosinophils from the
bone marrow and in their subsequent terminal differentiation. A study
was undertaken to determine whether inhaled and intravenous IL-5 could
induce pulmonary eosinophilia and bronchial hyperresponsiveness (BHR)
independently of these effects.
METHODSNine mild
asthmatics received inhaled (15 µg) or intravenous (2 µg) IL-5 or
placebo in random order in a double blind, crossover study. Blood
samples were taken before and at 0.5, 1, 2, 3, 4, 5, 24, and 72 hours
following IL-5 or placebo, and bronchial responsiveness (PC20 methacholine) and eosinophil counts in induced sputum
were determined.
RESULTSSerum IL-5
levels were markedly increased 30 minutes after intravenous IL-5
(p=0.002), and sputum IL-5 levels increased 4 and 24 hours after
inhaled IL-5 (p<0.05). Serum eotaxin was raised 24 hours after
intravenous IL-5 but not after inhaled IL-5 or placebo. Blood
eosinophils were markedly reduced 0.5-2 hours after intravenous IL-5
(p<0.05), followed by an increase at 3, 4, 5, and 72 hours (p<0.05).
Sputum eosinophils rose significantly in all three groups at 24 hours
but there were no differences between the groups. Bronchial
responsiveness was not affected by IL-5.
CONCLUSIONThe effects
of IL-5 appear to be mainly in the circulation, inducing peripheral
mobilisation of eosinophils to the circulation without any effect on
eosinophil mobilisation in the lungs or on bronchial responsiveness.
This article has been cited by other articles:
|
|
 |
|
  S.-W. Park, H. K. Jangm, M. H. An, J. W. Min, A.-S. Jang, J.-H. Lee, and C.-S. Park Interleukin-13 and Interleukin-5 in Induced Sputum of Eosinophilic Bronchitis: Comparison With Asthma Chest, October 1, 2005; 128(4): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Chang, J. S. Kim, J. H. Lee, J. I. Cho, T. Y. Rhim, S.-T. Uh, B. L. Park, I. Y. Chung, C.-S. Park, and H. D. Shin A Single Nucleotide Polymorphism on the Promoter of eotaxin1 Associates with Its mRNA Expression and Asthma Phenotypes J. Immunol., February 1, 2005; 174(3): 1525 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Kips, B. J. O'Connor, S. J. Langley, A. Woodcock, H. A. M. Kerstjens, D. S. Postma, M. Danzig, F. Cuss, and R. A. Pauwels Effect of SCH55700, a Humanized Anti-Human Interleukin-5 Antibody, in Severe Persistent Asthma: A Pilot Study Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1655 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Chung, E. L. J. van Rensen, R. G. Stirling, and P. J. Barnes Duplicate publication Am. J. Respir. Crit. Care Med., August 15, 2002; 166(4): 625 - 625. [Full Text] [PDF]
|
|
|
|
 |
|
 K F Chung, E van Rensen, R Stirling, and P J Barnes IL-5 in asthma Thorax, August 1, 2002; 57(8): 751 - 751. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
